{"id":"https://openalex.org/W2561499545","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","title":"Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC)","display_name":"Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC)","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2561499545","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","mag":"2561499545"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.7101","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033519199","display_name":"Kenneth John O'Byrne","orcid":"https://orcid.org/0000-0002-6754-5633","observed_orcids":["https://orcid.org/0000-0002-6754-5633"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"K. O'Byrne","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":null,"display_name":"L. Clarke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"L. Clarke","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085257858","display_name":"David J. Dunlop","orcid":"https://orcid.org/0000-0001-5351-7036","observed_orcids":["https://orcid.org/0000-0001-5351-7036"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"D. Dunlop","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055792960","display_name":"Malcolm Ranson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"M. Ranson","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070212769","display_name":"Sarah J. Danson","orcid":"https://orcid.org/0000-0002-3593-2890","observed_orcids":["https://orcid.org/0000-0002-3593-2890"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"S. Danson","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109077196","display_name":"N. Botwood","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"N. Botwood","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059652753","display_name":"David Paul Carbone","orcid":"https://orcid.org/0000-0003-3002-1921","observed_orcids":["https://orcid.org/0000-0003-3002-1921"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I4210154619","display_name":"St. James's Hospital","ror":"https://ror.org/04c6bry31","country_code":"IE","type":"healthcare","lineage":["https://openalex.org/I4210154619"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["GB","IE","US"],"is_corresponding":false,"raw_author_name":"D. Carbone","raw_affiliation_strings":["St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St James's Hospital, Dublin, Ireland; Beatson Oncology Centre, Glasgow, United Kingdom; Christie Hospital NHS Trust, Manchester, United Kingdom; AstraZeneca, Macclesfield, United Kingdom; Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I4210154619","https://openalex.org/I4390039299"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"7101","last_page":"7101"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/rofecoxib","display_name":"rofecoxib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8949999809265137},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.796999990940094},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor-inhibition","display_name":"epidermal growth factor receptor inhibition","score":0.906000018119812},{"id":"https://openalex.org/keywords/cox-2-inhibition","display_name":"COX-2 inhibition","score":0.9459999799728394},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.4429999887943268},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.7580000162124634},{"id":"https://openalex.org/keywords/serum-cytokines","display_name":"serum cytokines","score":0.6010000109672546},{"id":"https://openalex.org/keywords/surrogate-markers","display_name":"surrogate markers","score":0.5619999766349792},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9512773752212524},{"id":"https://openalex.org/C2778582115","wikidata":"https://www.wikidata.org/wiki/Q411412","display_name":"Rofecoxib","level":4,"score":0.8999587297439575},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.8651145696640015},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6674174070358276},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5624839663505554},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.5607091188430786},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4995403289794922},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47288623452186584},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.4574950635433197},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.40982016921043396},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4016179144382477},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3229258060455322},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2779843211174011},{"id":"https://openalex.org/C2779689624","wikidata":"https://www.wikidata.org/wiki/Q410251","display_name":"Cyclooxygenase","level":3,"score":0.2094300389289856},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.7101","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.7101","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.7101","doi":"https://doi.org/10.1200/jco.2004.22.90140.7101","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.7101","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2016002965","https://openalex.org/W2104387817","https://openalex.org/W2601402655","https://openalex.org/W2017249285","https://openalex.org/W2288039595","https://openalex.org/W2249281195","https://openalex.org/W2584365690","https://openalex.org/W2046501548","https://openalex.org/W2249607504","https://openalex.org/W1974441738"],"abstract_inverted_index":{"7101":[0],"Background:":[1],"The":[2,97,245],"epidermal":[3],"growth":[4],"factor":[5],"receptor":[6],"and":[7,21,33,64,115,161,202,209,213,235,255],"cyclooxygenase":[8],"2":[9,162],"(COX2)":[10],"may":[11,256],"be":[12,227,239],"targeted":[13],"with":[14,42,81,167,249],"inhibitors":[15],"such":[16],"as":[17],"gefitinib":[18,37,248],"(\u2018Iressa\u2019,":[19],"ZD1839)":[20],"rofecoxib,":[22],"respectively.":[23],"Methods:":[24],"This":[25],"Phase":[26],"I/II":[27],"study":[28],"evaluated":[29],"the":[30,71,82,103,242,263,272],"safety,":[31],"efficacy":[32],"pharmacokinetic":[34],"interactions":[35],"of":[36,53,76,180,187,192,247,265,271,275],"250":[38],"mg":[39,66],"po":[40,67],"daily":[41],"rofecoxib":[43,250],"in":[44,171,207,262],"platinum-pretreated":[45],"NSCLC.":[46,266],"Rofecoxib":[47],"was":[48,125,146],"escalated":[49],"through":[50],"3":[51],"cohorts":[52],"6":[54],"patients":[55,154],"from":[56,229],"12.5":[57],"(Level":[58,62,69],"1)":[59],"to":[60,86,128,143,260],"25":[61],"2)":[63],"50":[65],"od":[68],"3),":[70],"dose":[72],"at":[73,122,211,241],"which":[74],">90%":[75],"COX-2":[77],"activity":[78],"is":[79,91,233,251,268],"inhibited,":[80],"final":[83,236],"cohort":[84],"expanded":[85],"27":[87],"patients.":[88,96],"Results:":[89],"Analysis":[90],"complete":[92,159,234],"on":[93,139],"33":[94],"recruited":[95],"treatment":[98],"appears":[99],"generally":[100,252],"well":[101,253],"tolerated,":[102],"main":[104],"toxicities":[105],"including":[106],"skin":[107],"rash":[108],"(grade":[109,117],"1/2,":[110,118],"44%;":[111],"grade":[112,129],"3/4,":[113],"3%)":[114],"diarrhoea":[116],"22%).":[119],"One":[120],"patient":[121],"Level":[123],"1":[124,130,158],"withdrawn":[126],"due":[127],"renal":[131],"toxicity.":[132],"Another":[133],"had":[134],"a":[135,172,176,185,258,269],"cerebrovascular":[136],"accident":[137],"occurring":[138],"Day":[140],"31.":[141],"Time":[142],"tumour":[144],"progression":[145],"54":[147],"days":[148],"(range":[149],"46\u201364":[150],"days).":[151],"Of":[152],"31":[153],"evaluable":[155],"for":[156,184],"response,":[157],"response":[160,193],"partial":[163],"responses":[164],"were":[165],"seen,":[166],"stable":[168],"disease":[169,177],"recorded":[170],"further":[173],"9,":[174],"giving":[175],"control":[178],"rate":[179],"39%.":[181],"Preliminary":[182],"results":[183,237],"panel":[186],"potential":[188],"surrogate":[189],"serum/plasma":[190],"markers":[191],"indicate":[194],"that":[195],"IFN\u03b3,":[196],"TNF\u03b1,":[197],"IL2,":[198],"IL4,":[199],"IL6,":[200],"IL10":[201],"big-endothelin-1":[203],"levels":[204],"are":[205],"similar":[206],"responders":[208,225],"non-responders":[210],"baseline":[212],"over":[214],"time.":[215],"An":[216],"ongoing":[217],"global":[218],"serum":[219],"proteomic":[220],"analysis":[221],"will":[222,238],"assess":[223],"if":[224],"can":[226],"distinguished":[228],"non-responders.":[230],"Study":[231],"recruitment":[232],"presented":[240],"meeting.":[243],"Conclusion:":[244],"combination":[246],"tolerated":[254],"have":[257],"role":[259],"play":[261],"management":[264],"'Iressa'":[267],"trademark":[270],"AstraZeneca":[273,294],"group":[274],"companies":[276],"Author":[277],"Disclosure":[278],"Employment":[279],"or":[280,283],"Leadership":[281],"Consultant":[282],"Advisory":[284],"Stock":[285],"Ownership":[286],"Honoraria":[287],"Research":[288],"Funding":[289],"Expert":[290],"Testimony":[291],"Other":[292],"Remuneration":[293],"Pharmaceuticals":[295]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-06T00:00:00"}